<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>IPCALAB</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">IPCALAB</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="ipca-laboratories-limited" class="section level1">
<h1>IPCA Laboratories Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.IPCALAB.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.IPCALAB.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.IPCALAB.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.IPCALAB.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.IPCALAB.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.IPCALAB.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.IPCALAB.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.IPCALAB.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.IPCALAB.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-03 </em></p>
<div id="ipca-laboratories-limited-ipcalab-analysis-headwinds-tailwinds-growth-prospects-and-key-risks" class="section level9">
<p class="heading">Ipca Laboratories Limited (IPCALAB) Analysis: Headwinds, Tailwinds, Growth Prospects, and Key Risks</p>
<p>Ipca Laboratories reported strong Q2/H1 FY26 results with revenue growth (standalone +7-9%, consolidated +9-10%), margin expansion (standalone EBITDA ~25%, consolidated ~22%), and profit growth (+23-26%). Domestic formulations drove growth amid export softness, with API shining (+28% Q2). Management guided for 10-11% domestic growth, 8-9% export generics recovery in H2, 14-15% API growth, and improved margins (~21% consolidated). Unichem synergies are progressing, and a biosimilar tech transfer deal adds upside. Below is a structured summary based on the earnings call, financials, and announcements.</p>
<div id="tailwinds-positive-drivers" class="section level12">
<p class="heading"><strong>Tailwinds (Positive Drivers)</strong></p>
<ul>
<li><strong>Margin Expansion &amp; Cost Discipline</strong>: Standalone EBITDA margin up 257 bps YoY to 25.46% (Q2) due to better product mix (chronic/acutes), lower material costs (-3-4%), and stable opex. Consolidated at 21.68% (+258 bps). Guidance for +1% improvement in H2 from mix and Unichem stabilization.</li>
<li><strong>Robust Domestic Formulations</strong>: +8% Q2/+9% H1 growth, outpacing IPM (acute +8.2% vs. 6.2%; chronic +14.2% vs. 10.3%). Market share up to 2.8% (MAT Sep’25), rank ~16. Pain (+10-11%), CV (+11% Q2), CNS (+18%), derma/urology (+11%) strong; chronic share rising to 35%.</li>
<li><strong>API Strength</strong>: +28% Q2 (INR 408 Cr) from Europe/LatAm; H1 +14-15% FY guidance. High-margin volumes aiding profitability.</li>
<li><strong>Unichem Synergies</strong>: Logistics/energy costs cut; 12 dossiers filed for Europe/others (approvals in 1-1.5 yrs). API sourcing from Ipca post-approvals (6-9 months). Q2 EBITDA ~INR 60 Cr (11%); margins to 15-20% in 1.5-2 yrs. EU penalty settled (INR 58 Cr exceptional hit).</li>
<li><strong>R&amp;D Momentum</strong>: Spend at 3.91% (Q2), targeting 4% FY/~4.5% FY27. 30-35 filings capacity (US: 2 filed, 5-6 pipeline); biosimilars (7 projects, 3 to trials FY27).</li>
<li><strong>Strategic Deals</strong>: Tech transfer of mAb biosimilar to BSS (US/PR) – milestones + royalties; targets USD 4 Bn US market (12% CAGR). Enhances US foothold.</li>
</ul>
</div>
<div id="headwinds-challenges" class="section level12">
<p class="heading"><strong>Headwinds (Challenges)</strong></p>
<ul>
<li><strong>Export Formulations Softness</strong>: Q2 -9% (INR 493 Cr), H1 flat due to inventory drawdown in one key product and institutional weakness (-29% Q2). Generics -6% Q2; US building slowly (H1 INR 55 Cr).</li>
<li><strong>GST Rationalization Impact</strong>: Sep’25 domestic slowdown (low growth); antimalarials -8% Q2/-2% H1. Temporary, with Oct recovery.</li>
<li><strong>Unichem Transition</strong>: Q1 restructuring/EU forex hit; inventory high (3 months US norm, reduced INR 150 Cr Q2). Gross margins dipped to 54-55% from volume/market share loss in key US products.</li>
<li><strong>Subsidiary Drag</strong>: Lyka impacted by GST/P2P delays/rejections (INR 5-7 Cr hit).</li>
<li><strong>Opex Pressure</strong>: Employee costs +8%, marketing +6-7%; R&amp;D up sharply.</li>
</ul>
</div>
<div id="growth-prospects" class="section level12">
<p class="heading"><strong>Growth Prospects</strong></p>
<table>
<colgroup>
<col width="17%" />
<col width="45%" />
<col width="37%" />
</colgroup>
<thead>
<tr class="header">
<th>Segment</th>
<th>FY26 Guidance/Outlook</th>
<th>Long-Term Drivers</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Domestic</strong></td>
<td>10-11%</td>
<td>Chronic mix to 40%+; new divisions (cosmetic derma, Flexicare pain); 7,000 MRs (+400-500/yr cap). GLP-1 via in-licensing (biotech R&amp;D ramping).</td>
</tr>
<tr class="even">
<td><strong>Exports (Generics)</strong></td>
<td>8-9% H2; 9-10% branded FY</td>
<td>Europe recovery ex-one product; US ramp (6 shipped, 5-6 manuf.; INR 14-15 Cr/Q). Unichem US +8-10%; dossier expansions (Europe/Aus/NZ/Canada).</td>
</tr>
<tr class="odd">
<td><strong>API</strong></td>
<td>14-15%</td>
<td>Europe/LatAm sustained; low-volume to high-margin shift.</td>
</tr>
<tr class="even">
<td><strong>US/Biosimilars</strong></td>
<td>Conservative ramp</td>
<td>5-6 new APIs; biosimilars clinical FY27; tech transfer royalties (2027+ launch). Pipeline focus on own APIs.</td>
</tr>
<tr class="odd">
<td><strong>Overall</strong></td>
<td>10%+ revenue; 21-22% EBITDA</td>
<td>Unichem portfolio extension; R&amp;D filings; cash generative (H1 op. cash INR 651/780 Cr standalone/consol). Surplus post-Jogeshwari land sale.</td>
</tr>
</tbody>
</table>
<ul>
<li><strong>5-Year View</strong>: US scaling via own APIs/biosimilars; ROW expansion; chronic/GLP-1 entry. Biosimilar deal accelerates US presence.</li>
</ul>
</div>
<div id="key-risks" class="section level12">
<p class="heading"><strong>Key Risks</strong></p>
<table>
<colgroup>
<col width="41%" />
<col width="25%" />
<col width="33%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Details</th>
<th>Mitigation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Regulatory/Compliance</strong></td>
<td>Past EU issues (settled); US filings delays; biosimilar trials.</td>
<td>R&amp;D filings accelerating; partner expertise (BSS).</td>
</tr>
<tr class="even">
<td><strong>Competition/ Pricing</strong></td>
<td>US generics erosion (Unichem lost share in 2 products); no shortages = lower margins.</td>
<td>Own APIs; new launches (2-3/yr Unichem); tender cycles.</td>
</tr>
<tr class="odd">
<td><strong>Forex/ Macro</strong></td>
<td>Unrealized losses (INR 39/43 Cr H1); euro weakness hit Unichem.</td>
<td>Hedging; 50% exports.</td>
</tr>
<tr class="even">
<td><strong>Execution</strong></td>
<td>Unichem integration (1.5-2 yrs); R&amp;D cost spike (4.5%+ FY27); US maturity (conservative).</td>
<td>Surplus cash; cost cuts done.</td>
</tr>
<tr class="odd">
<td><strong>Market/ Dependency</strong></td>
<td>Antimalarials decline; institutional volatility; GST seasonality.</td>
<td>Diversification (chronic/pain/CV); IPM outperformance.</td>
</tr>
<tr class="even">
<td><strong>Subsidiary</strong></td>
<td>Lyka/others volatility; NCI losses.</td>
<td>Monitoring; cash independence.</td>
</tr>
</tbody>
</table>
<p><strong>Overall Summary</strong>: Ipca is in a strong recovery phase with tailwinds from margins, domestic share gains, and API dominating headwinds (export H1 softness, GST). Growth prospects are solid (10%+ FY26, US/biosimilars upside), supported by R&amp;D and Unichem. Risks are manageable (mostly execution/competition), with healthy balance sheet (net cash positive post-debt paydown). Bullish medium-term outlook; stock could re-rate on margin delivery and US catalysts. Monitor H2 exports and Unichem margins.</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
